Ranbaxy Daiichi Sankyo Merger

Introduction
Indias largest pharmaceutical company. Incorporated in 1961 Atul Sobti is currently Ranbaxy CEO and Managing Present Chairman- Dr. Tsutomu Une Exports its products to 125 countries Ground operations in 46 countries Manufacturing facilities in 7 countries. HQ: Gurgaon, Haryana.

Director

History
Started by Ranbir Singh and Gurbax Singh in 1937. In 1998, Ranbaxy entered the United States market Japanese company Daiichi Sankyo gained majority control in 2008.

Financials
2008- Global Sales of US $ 1,682 Million Growth of 4%. North America, the Company's largest market contributed sales of US $ 449 Million India clocking sales of around US $ 300 Million Market share in India is 5%

Major Setback
December 2005, Ranbaxy's shares hit hard by a patent ruling disallowing production of its own version of Pfizers drug Lipitor. September 2008, the FDA issued two Warning Letters to Ranbaxy and an Import Alert for generic drugs produced by two manufacturing plants in India.

Product portfolio
Anti-Infectives Cardiovascular Diabetes Dermatological Neuro-Psychiatry Pain management Gastro-Intestinal Nutritional A strong player in the NDDS segment. Biological formulations such as Verorab (Rabies Vaccine) and Vaxigrip (Flu Vaccine),

Major Alliances / Collaborations

Drug Discovery & Clinical Development GlaxoSmithKline (Anti-infective and Respiratory Segments) Drug Discovery Clinical Development Merck Statin molecule out licensed to PPD, USA

Introduction
Japan based pharmaceutical company. Established in 2005 - merger of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd. Head Office Tokyo Leading company in the field of cardiovascular drugs. Workforce - 29,272 people (as of September 30,2009) Capital - 50 billion yen U.S. subsidiary, Daiichi Sankyo, Inc. (DSI) European subsidiary, Daiichi Sankyo Europe GmbH (DSE)

History
Sankyo
Established in 1913

Daiichi Pharmaceutical
Established in 1918 September 28, 2005 - DAIICHI SANKYO COMPANY, LIMITED

2006 Started operation of DAIICHI SANKYO HEALTHCARE CO., LTD. Started operations of DAIICHI SANKYO Inc. Started operations of Daiichi Sankyo Europe GmbH

April 1, 2007- started operations as the newly formed DAIICHI SANKYO Group

Research and Development

GEMRAD (Global Executive Meeting of Research And Development) - top research and development decisionmaking body. Research focusing on the six areas of cardiovascular diseases, glucose metabolic disorders, infectious diseases, cancer, immunity and allergies, and bones/joint diseases. Core Development Areas: Thrombosis, Diabetes, Malignant Neoplasm, and Autoimmune Diseases Franchise areas: Hypertension, Bacterial Infections, and Hyperlipidemia / Atherosclerosis

Products
Sankyo -

Benicar (olmesartan medoxomil) Mevalotin (pravastatin) Loxonin (loxoprofen) Olmetec (olmesartan) Captopril Zantac (ranitidine) WelChol (colesevelam HCl) Effient (Prasugrel)

 Daiichi Pharmaceutical

Cravit (levofloxacin) Evoxac (cevimeline) FloxinOtic (ofloxacin) Gracevit (sitafloxacin, only sold in Japan)

RANBAXY-DAIICHI SANKYO
THE DEAL

THE DEAL
Provide Stronger Platform for Drug Development, Manufacturing & Global Reach Aim to be Research based International Pharmaceutical Company.

THE DEAL
34.8% stake worth 10,000 crores($2.4 billion) At Rs 737 per share Daiichi will pick up another 9.4% through Preferential Allotment Open offer of 20% to Shareholders of Ranbaxy

THE DEAL
On June 11 2008, Daiichi Sankyo acquired a 34.8% stake in Ranbaxy valued at $2.4 billion. In November 2008, Daiichi-Sankyo completed the takeover of the company from the founding Singh family in a deal worth $4.6 billion by acquiring a 63.92% stake in Ranbaxy.

THE DEAL
Mr. Singh plans to Invest his $2.4 billion in: Financial Services & Hospitals Religare Fortis

WHY RANBAXY DID IT ?

A very intelligent deal Had held share for 50 years But the Ranbaxy growth curve had peaked 2006 16% growth 2007 7% growth 2009- 9% growth forecast Business model was struggling with high litigation costs and devaluation of the rupee against the USD US strategy was looking in the face of more expensive litigation

Selling of entire stake at 30% premium

WHY DAICHI DID IT ?

Japan has an ageing population and they needed new market There is growing recognition in Japan of the importance of generic drugs Japanese health Ministry is encouraging doctors to use generic drugs to reduce the health budget Acquisition of Ranbaxy gives Daiichi a low cost manufacturing base in India Daiichi will have a strong generics operations in India and operations in 60 different countries

Daiichi moves from 22nd rank to 15th among world largest pharmaceutical companies

EFFECTS ON PHARMA INDUSTRY

THE EFFECTS ON RANKINGS

Before Merger Ranbaxy 8th largest Generic Drug Maker in the World Daiichi Sankyo 25th Largest Pharmaceuticle Company in the World After Merger Ranbaxy Daiichi 15th Largest Pharmaceutical Company Ranbaxy to be among the top five Generic Drug makers in the world

The New Trend

RANBAXY a Generics Maker

Daiichi: an Innovator

A Merger termed as the Ardhnarishwar Model

MARKET PENETRATION
Ranbaxy gets a support in the R&D Sector where it lags Daiichi forays in the Generics sector with Indias largest Generics Manufacturer Penetration of Ranbaxy in Japanese market made easy and same for Daiichi in India

For Ranbaxy
Significant milestone in becoming a research-based international pharmaceutical company. Ranbaxy will gain easier access to the much-coveted Japanese market by operating from within the Daiichi Sankyo The immediate benefit for Ranbaxy is that the deal frees up its debt and imparts more flexibility into its growth plans.

For Daiichi
Easier to enter the Indian market. Bigger goal - in securing a strong presence in the global market for generics. The acquisition will help Daiichi Sankyo to jump from number 22 in the global pharmaceutical sector to number 15. The main benefit is Ranbaxys low-cost manufacturing infrastructure and supply chain strengths.

 Will be able to reduce its reliance on only branded drugs and margin risks in mature markets. Benefit from Ranbaxys strengths in generics to introduce generic versions of patent expired drugs, particularly in the Japanese market. Additional NDAs from the US FDA on antihistaminics and anti-diabetics is an added advantage.

For the Joint Venture

A complementary business combination that provides sustainable growth by diversification that spans the full spectrum of the pharmaceutical business. An expanded global reach that enables leading market positions in both mature and emerging markets with proprietary and non-proprietary products. Strong growth potential by effectively managing opportunities across the full pharmaceutical life-cycle. Cost competitiveness by optimizing usage of R&D and manufacturing facilities of both companies, especially in India.

 Both companies acquire a broader product base, therapeutic focus areas and well distributed risks.

Effect of deal on India as whole

1) Loss of good influencing people from pharma sector 2)Maximum use of available natural resources and not rational use. 3) Use the Indian talent in good manner at cheap rate. 4)Capture of rich Indian generic store.

Common influences of merger on both Daichii and Ranbaxy

Reduced competition & choice for consumer in oligopoly market Likelihood of job cuts

Conflict with new management

Difficulty in cultural integration Monetory cost to the company

Happenings with Ranbaxy after merger

US regulator plan to stop reviewing any drug made at Paonta Shahib (one of the Ranbaxy Indian plant) Ranbaxy failed to secure the American drug regulators permission to market generic drug in US.(Astellas ,Flomax) Ban on import of around 30 generic drug by FDA US Financial loss

Impact of it on Daiichi
Daichii have to face competitor of Ranbaxy Ranbaxy acquisition puts Daiichi Sankyo in red Price Daiichi paid for acquisition was quite high compared to the present pricing of other Indian generic drug making companies. Lots of government restrictions on Ranbaxy drug Daiichi has to appoint industry experts to resolve issues related to the USFDA

Impact of it on Daiichi
Daiichi Sankyo's Loss Forecast The FDA's latest findings come less than a month after Daiichi Sankyo reported a $3.7 billion loss in the OctoberDecember quarter and warned that annual earnings would swing to a loss. The Tokyo-based company now expects a net loss of $3.2 billion this fiscal year through March, instead of the previously predicted $663 million gain, largely because of the yen's recent strength and the Ranbaxy deal The currency hedges by Ranbaxy would cost the Japanese drugmaker around $122 million this financial year

Impact of it on Daiichi
Japan accounts for 68 per cent of Daiichi Sankyos sales, with North America being the second largest market contributing 20 per cent, followed by Europe with 9 per cent and other markets 3 per cent. SoThe fourth-quarter net loss of the Japanese pharma giant amounts to $390.1 million, which has been attributed to the acquisition of Ranbaxy. Daiichi Sankyo might have been deceived by Ranbaxy by analyst Fumiyoshi Sakai. Expiring of Ranbxy patent cutting down the royalty payment

Effect on Indian Pharmaceutical Industry

Ranbaxy fell 3% on stock market because of low acceptance and capital gains Hence, proving the deal to be disadvantage to the industry